阻断人蛋白C抗凝活性可改善表达人蛋白C的血友病小鼠的凝血缺陷
本研究使用基因替换人蛋白C的F8-/-或F9-/-血友病小鼠,测试单克隆抗体HAPC1573选择性阻断人活化蛋白C(APC)抗凝活性的治疗潜力。HAPC1573预处理缩短了PROC+/+;F8-/-小鼠尾出血时间,在膝关节针刺出血模型中显著降低死亡率并减轻关节肿胀,效果与FVIII或FIX治疗相似。HAPC1573还显著改善PROC+/+;F8-/-小鼠的凝血酶生成,并改善缺乏FVIII、FIX、FXI、FVII、VWF、FV或FX的人血浆凝血时间。
要点
- HAPC1573预处理缩短PROC+/+;F8-/-血友病小鼠尾出血时间。
- HAPC1573降低膝关节出血模型死亡率并减轻关节肿胀,与FVIII或FIX相似。
- HAPC1573改善PROC+/+;F8-/-小鼠凝血酶生成,对F8-/-小鼠无此作用。
核心结论
- 选择性阻断人APC抗凝活性可能是缺乏FVIII、FIX或其他凝血因子所致出血性疾病的有效治疗和/或预防方法。
研究设计与样本
- 研究使用F8-/-或F9-/-血友病小鼠,通过基因替换将小鼠Proc基因替换为人PROC,生成表达人蛋白C的PROC+/+;F8-/-或PROC+/+;F9-/-小鼠。
- 评估单克隆抗体HAPC1573选择性阻断人APC抗凝活性的治疗潜力。
主要发现
- PROC+/+;F8-/-或PROC+/+;F9-/-小鼠出血特征与相应F8-/-或F9-/-小鼠相似。
- HAPC1573预处理缩短PROC+/+;F8-/-小鼠尾出血时间。
- 在膝关节针刺出血模型中,HAPC1573预处理显著降低PROC+/+;F8-/-或PROC+/+;F9-/-小鼠死亡率并减轻关节肿胀,与FVIII或FIX治疗相似。
- HAPC1573显著改善PROC+/+;F8-/-小鼠凝血酶生成,但不改善F8-/-小鼠,表明HAPC1573通过调节体内人APC增强血友病小鼠凝血活性。
- HAPC1573抑制APC抗凝活性,改善缺乏FVIII、FIX、FXI、FVII、VWF、FV或FX的人血浆凝血时间。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia A and B are hereditary coagulation defects resulting in unstable blood clotting and recurrent bleeding. Current factor replacement therapies have major limitations such as the short half-life of the factors and development of inhibitors. Alternative approaches to rebalance the hemostasis by inhibiting the anticoagulant pathways have recently gained considerable interest. In this study, we tested the therapeutic potential of a monoclonal antibody, HAPC1573, that selectively blocks the anticoagulant activity of human activated protein C (APC). We generated F8-/- or F9-/- hemophilia mice expressing human protein C by genetically replacing the murine Proc gene with the human PROC. The resulting PROC+/+;F8-/- or PROC+/+;F9-/- mice had bleeding characteristics similar to their corresponding F8-/- or F9-/- mice. Pretreating the PROC+/+;F8-/- mice with HAPC1573 shortened the tail bleeding time. HAPC1573 pretreatment significantly reduced mortality and alleviated joint swelling, similar to those treated with either FVIII or FIX, of either PROC+/+;F8-/- or PROC+/+;F9-/- mice in a needle puncture-induced knee-joint bleeding model. Additionally, we found that HAPC1573 significantly improved the thrombin generation of PROC+/+;F8-/- mice but not F8-/- mice, indicating that HAPC1573 enhanced the coagulant activity of hemophilia mice by modulating human APC in vivo. We further documented that HAPC1573 inhibited the APC anticoagulant activity to improve the clotting time of human plasma deficient of FVIII, FIX, FXI, FVII, VWF, FV, or FX. These results demonstrate that selectively blocking the anticoagulant activity of human APC may be an effective therapeutic and/or prophylactic approach for bleeding disorders lacking FVIII, FIX, or other clotting factors.
引用
- Jiang M, Yang F, Jiang Y, et al. Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C. Blood Adv. 2022. PMID: 35390147. doi:10.1182/bloodadvances.2021006214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。